Free Trial

Charles River Laboratories International (CRL) 10K Form and Latest SEC Filings 2026

Charles River Laboratories International logo
$177.96 -3.72 (-2.05%)
Closing price 03:59 PM Eastern
Extended Trading
$177.60 -0.35 (-0.20%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Charles River Laboratories International SEC Filings & Recent Activity

Charles River Laboratories International (NYSE:CRL) has submitted 633+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Charles River Laboratories International's financial statements. The most recent filing was a Form S-8 submitted on May 7, 2026.

Form 4
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Reports Ownership Change on May. 4, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Charles River Laboratories International Files Current Report on May. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Charles River Laboratories International Files Annual Report on Feb. 18, 2026

The 10-K contains Charles River Laboratories International's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Charles River Laboratories International SEC Filing History

Browse Charles River Laboratories International's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/07/2026 3:56 PM
Charles River Laboratories International (1100682) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/07/2026 6:14 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2026 2:45 PM
Charles River Laboratories International (1100682) Subject
Invesco Ltd. (914208) Filed by
Form SCHEDULE 13G/A
05/06/2026 10:06 AM
Charles River Laboratories International (1100682) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G
05/04/2026 4:16 PM
Charles River Laboratories International (1100682) Issuer
Coleman Glenn (1434369) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2026 4:49 PM
Charles River Laboratories International (1100682) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/08/2026 3:53 PM
Charles River Laboratories International (1100682) Issuer
Coleman Glenn (1434369) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/31/2026 6:50 AM
Charles River Laboratories International (1100682) Filer
Form DEF 14A
03/31/2026 6:54 AM
Charles River Laboratories International (1100682) Filer
Form ARS
03/26/2026 4:15 PM
Charles River Laboratories International (1100682) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/05/2026 4:18 PM
Charles River Laboratories International (1100682) Issuer
Girshick Birgit (1732091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 3:39 PM
Charles River Laboratories International (1100682) Issuer
LaPlume Joseph W (1767215) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 3:42 PM
Charles River Laboratories International (1100682) Issuer
FOSTER JAMES C (1141722) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2026 6:34 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/18/2026 3:39 PM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/18/2026 8:21 AM
Charles River Laboratories International (1100682) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/18/2026 6:13 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/12/2026 12:51 PM
Charles River Laboratories International (1100682) Subject
Invesco Ltd. (914208) Filed by
Form SCHEDULE 13G
02/10/2026 10:19 AM
Charles River Laboratories International (1100682) Subject
Form SCHEDULE 13G/A
02/03/2026 3:36 PM
Charles River Laboratories International (1100682) Issuer
LaPlume Joseph W (1767215) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 3:39 PM
Charles River Laboratories International (1100682) Issuer
Knell Michael Gunnar (1543779) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 3:42 PM
Charles River Laboratories International (1100682) Issuer
Girshick Birgit (1732091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 3:46 PM
Charles River Laboratories International (1100682) Issuer
FOSTER JAMES C (1141722) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 7:49 AM
Charles River Laboratories International (1100682) Issuer
LaPlume Joseph W (1767215) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 7:10 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/09/2026 3:18 PM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2025 6:28 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/17/2025 7:06 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2025 8:33 AM
Charles River Laboratories International (1100682) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
11/07/2025 3:35 PM
Charles River Laboratories International (1100682) Issuer
Knell Michael Gunnar (1543779) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/05/2025 8:12 AM
Charles River Laboratories International (1100682) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/05/2025 6:16 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/19/2025 3:14 PM
Charles River Laboratories International (1100682) Filer
Form 8-K/A
09/16/2025 6:10 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/22/2025 12:37 PM
Charles River Laboratories International (1100682) Subject
LaPlume Joseph W (1767215) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/20/2025 3:45 PM
Charles River Laboratories International (1100682) Issuer
LaPlume Joseph W (1767215) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2025 12:27 PM
Charles River Laboratories International (1100682) Subject
LaPlume Joseph W (1767215) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2025 4:41 PM
Charles River Laboratories International (1100682) Subject
NOMURA HOLDINGS INC (1163653) Filed by
Form SCHEDULE 13G
08/08/2025 3:18 PM
Charles River Laboratories International (1100682) Issuer
LaPlume Joseph W (1767215) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2025 8:07 AM
Charles River Laboratories International (1100682) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/06/2025 6:08 AM
Charles River Laboratories International (1100682) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2025 3:34 PM
Charles River Laboratories International (1100682) Subject
WALLMAN RICHARD F (1198092) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/10/2025 3:22 PM
Charles River Laboratories International (1100682) Issuer
Mintz Mark (2071546) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/09/2025 3:21 PM
Charles River Laboratories International (1100682) Issuer
LaPlume Joseph W (1767215) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 3:40 PM
Charles River Laboratories International (1100682) Issuer
Graves Paul W (1559551) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 3:42 PM
Charles River Laboratories International (1100682) Issuer
Enyedy Mark J (1586965) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 3:45 PM
Ceesay Abraham (1722140) Reporting
Charles River Laboratories International (1100682) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 3:38 PM
Barg Steven (1852883) Reporting
Charles River Laboratories International (1100682) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 3:46 PM
Charles River Laboratories International (1100682) Issuer
FOSTER JAMES C (1141722) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 3:49 PM
Charles River Laboratories International (1100682) Issuer
Creamer Victoria L (1632780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 3:52 PM
Charles River Laboratories International (1100682) Issuer
Girshick Birgit (1732091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2025 4:18 PM
Charles River Laboratories International (1100682) Issuer
Graves Paul W (1559551) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/29/2025 4:23 PM
Charles River Laboratories International (1100682) Issuer
Enyedy Mark J (1586965) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/29/2025 4:26 PM
Barg Steven (1852883) Reporting
Charles River Laboratories International (1100682) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/29/2025 4:29 PM
Ceesay Abraham (1722140) Reporting
Charles River Laboratories International (1100682) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/29/2025 3:54 PM
Charles River Laboratories International (1100682) Issuer
Creamer Victoria L (1632780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2025 3:58 PM
Charles River Laboratories International (1100682) Issuer
Girshick Birgit (1732091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:08 PM
Andrews Nancy C (1804999) Reporting
Charles River Laboratories International (1100682) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2025 3:38 PM
Charles River Laboratories International (1100682) Issuer
LaPlume Joseph W (1767215) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2025 3:41 PM
Charles River Laboratories International (1100682) Issuer
MASSARO GEORGE (1221496) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2025 2:33 PM
Charles River Laboratories International (1100682) Subject
LaPlume Joseph W (1767215) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/12/2025 9:44 AM
Charles River Laboratories International (1100682) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Charles River Laboratories International SEC Filings - Frequently Asked Questions

Charles River Laboratories International (CRL) has submitted 633+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Charles River Laboratories International's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Charles River Laboratories International's financial statements page.

The most recent filing was a Form S-8 submitted on May 7, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSE:CRL) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners